Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population

Stintzing, Sebastian; Modest, Dominik Paul; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmueller, C.; Kahl, Christoph; Seipelt, G.; Kullmann, Frank; Scheithauer, Werner; Held, Swantje; Gießen, Clemens; Moehler, Markus; Jagenburg, A.; Jung, Andreas; Kirchner, Thomas; Heinemann, Volker

doi:10.1093/annonc/mdu438.9

Cited by 51 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a recent review has indicated [8], DpR was significantly associated with OS as well as PPS in our study, suggesting a positive correlation between PPS and OS. Our findings support previously reported evidence from several trials indicating that DpR may predict the outcomes of patients who receive initial chemotherapy [11,13,17]. Moreover, Spearman's correlation coefficient between DpR and PPS was 0.366, nearly equivalent to the correlation coefficients in the CRYSTAL and OPUS studies, based on longest tumor diameter (0.40 and 0.50, respectively) [3].…”

Section: Discussionsupporting

confidence: 90%

“…The CRYSTAL, OPUS, and FIRE-3 studies reported rates of ETS ranging from 62 % to 69 %, and early response correlated with better survival time [14,15,17]; however, few studies have prospectively evaluated the relation between ETS and survival. The results of our phase II trial, which included an evaluation of the predictive value of ETS, prospectively showed that ETS had a prognostic impact on both PFS and OS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

et al. 2016

View full text Add to dashboard Cite

show abstract

“…arm may explain in part the significant OS advantage [16]. This result implies that responses to therapy might not be adequately evaluated when performed by only using RECIST; however, RECIST-independent tumorsize metrics such as DpR can better predict or categorize patients who will respond to therapy or survive longer.…”

Section: Discussionmentioning

confidence: 99%

2317 Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

Jung¹,

Lee²,

Jin³

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

Purpose: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab.Results: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Cτ indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoff value, as it was best able to identify patients with longer PFS (median 9.0 vs. Materials and Methods: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoff values of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS).Conclusions: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.

show abstract

“…Furthermore, bevacizumab used in the neoadjuvant chemotherapy schedule seems to induce better pathological response than anti-EGFR [45]. On the other hand, depth of response seemed to be increased with cetuximab as compared to bevacizumab [103]. Hence, additional studies are warranted to solve this therapeutic dilemma [104, 105•].…”

Section: Other Targeted Agents In Metastatic Colorectal Cancermentioning

confidence: 99%

Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit

Innominato

Adam

2016

Curr Colorectal Cancer Rep

View full text Add to dashboard Cite

Liver metastases are a frequent and commonly lethal complication of colorectal cancer. Surgical resection of limited liver disease offers currently the best chance of longterm survival, but surgery is not feasible for a rather significant proportion of patients with hepatic metastases. Despite the overall improvement in the medical management of patients with metastatic colorectal cancer, whose median survival has been substantially prolonged with the availability of novel drugs, long-term outcomes remain rather poor if a combined onco-surgical strategy cannot be implemented. Nonetheless, newer chemotherapy schedules have become more frequently, rapidly and deeply active, improving hepatic lesions' downsizing, hence extending the pool of patients amenable to secondary liver surgery. Here, we summarize available data on the efficacy and safety of bevacizumab, an anti-VEGF monoclonal antibody indicated for the treatment of metastatic colorectal cancer, as a conversion chemotherapeutic option in the management of patients with liver metastases.

show abstract

Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population

Cited by 51 publications

References 0 publications

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

2317 Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit

Contact Info

Product

Resources

About